Choose language

en
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

English
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

How do you prefer to top up your account?

* We don't charge any commission for making deposits into your account

Gilead Sciences

GILD.US $ 69.84 USD

0.23 $ (0.33%)

Growth potential

6.73%

Dividend income

3.49%

1d
1w
1mo
6mths
All the time

Add to cart

1 lot = 1 stock

Purchase amount:

Brokerage commission:

Transfer commission:

Recommendation

Strong Buy

Performance Rating

DCF

73.28

ROE

0.01

ROA

-

P/S

3.33

P/B

4.52

Debt / Equity

1.57

About Company

Gilead Sciences is the largest American biopharmaceutical company engaged in research and development of healthcare products and has a batch production of innovative medicines. The Company was founded in 1987 by a 29-year-old doctor Michael L. Riordan. Gilead's technologies, as well as the drugs themselves, have established themselves as a leading choice when it comes to prevention and cure of the most fatal human diseases. The Company's main efforts have been focused on HIV cure development as well as various treatments of chronic hepatitis B and C, cancers, cardiovascular and respiratory diseases. Among the well-known products are Tamiflu, Atripla, Vistide, Emtriva. The latest successful project of Gilead was Sovaldi, which is an effective medicine for hepatitis C cure. The innovation has become an all-time record of sales. The company's research centers are located in the American cities of Boulder and San Dimas. The company has a rather small staff number, which is about 8,000 employees, with a fairly large turnover of almost $ 25 billion. Today Gilead Sciences boasts of being one of the most speedily developing start-ups in its field. Its headquarters are in California, though the company has its representative offices in other states of North America, as well as in Europe, Asia, and Australia.


Sign up for investment ideas from Freedom Finance analysts

We will send an e-mail once a week containing only the most relevant and important information

Congratulations!

Now you will always be aware of which stocks are more profitable to invest in